Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1235-1248

  Huang, Yuting ^a   Ju, Baohui ^a,b   Tian, Jing ^a   Liu, Fenghua ^a   Yu, Hu ^a   Xiao, Huiting ^a   Liu, Xiangyu ^a   Liu, Wenxin ^a   Yao, Zhi ^a   Hao, Quan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ALVESPIMYCIN; ATROPINE; BENZTHIAZIDE; CINCHONINE; DIETHYLSTILBESTROL; DISULFIRAM; DOXYLAMINE; ESCULETIN; LYCORINE; MEMBRANE RECEPTOR; NALTREXONE; PHENAZONE; PRALIDOXIME; PUROMYCIN; PYRIMETHAMINE; TANESPIMYCIN; THAPSIGARGIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASEMENT MEMBRANE; CANCER STEM CELL; CELL CYCLE REGULATION; CELL SPECIFICITY; CENTROSOME; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MAPPING; GENE REGULATORY NETWORK; GENETIC DATABASE; GREB1 GENE; HUMAN; HUMAN CELL; KLF9 GENE; MTUS1 GENE; NAB1 GENE; NPIPL1 GENE; OVARY CANCER; PPM1D GENE; PRIORITY JOURNAL; PROS1 GENE; RECEPTOR BINDING; UPREGULATION;

ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; TRANSCRIPTOME;

EID: 84896737061     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2976     Document Type: Article

References (48)

1. Dingli D and Michor F: Successful therapy must eradicate cancer stem cells. Stem Cells 24: 2603-2610, 2006. (Pubitemid 46052998)
2. Frank NY, Schatton T and Frank MH: The therapeutic promise of the cancer stem cell concept. J Clin Invest 120: 41-50, 2010.
3. Clarke-Pearson DL: Clinical practice. Screening for ovarian cancer. N Engl J Med 361: 170-177, 2009.
4. Zhang S, Balch C, Chan MW, et al: Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320, 2008.
5. Rahman MT, Nakayama K, Rahman M, et al: Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol 138: 535-544, 2012.
6. McAuliffe SM, Morgan SL, Wyant GA, et al: Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA 109: E2939-E2948, 2012.
7. Gene Ontology Consortium: The Gene Ontology project in 2008. Nucleic Acids Res 36: D440-D444, 2008.
8. Kanehisa M, Goto S, Kawashima S, Okuno Y and Hattori M: The KEGG resource for deciphering the genome. Nucleic Acids Res 32: D277-D280, 2004. (Pubitemid 38081656)
9. Lamb J, Crawford ED, Peck D, et al: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935, 2006. (Pubitemid 44497995)
10. Lee JK, Havaleshko DM, Cho H, et al: A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 104: 13086-13091, 2007. (Pubitemid 351737597)
11. Rizzo S, Hersey JM, Mellor P, et al: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 10: 325-335, 2011.
12. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L and Birrer MJ: Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 7: e29079, 2012.
13. Wang L, Mezencev R, Bowen NJ, Matyunina LV and McDonald JF: Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem 363: 257-268, 2012.
14. Bonome T, Levine DA, Shih J, et al: A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486, 2008.
15. Ozols RF: Treatment goals in ovarian cancer. Int J Gynecol Cancer 15 (Suppl 1): 3-11, 2005.
16. Bapat SA, Mali AM, Koppikar CB and Kurrey NK: Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029, 2005. (Pubitemid 40524578)
17. Gotoh S, Nakamura T, Kataoka T and Taketani S: Egr-1 regulates the transcriptional repression of mouse δ-aminolevulinic acid synthase 1 by heme. Gene 472: 28-36, 2011.
18. Munksgaard PS and Blaakaer J: The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 124: 164-169, 2012.
19. Grigo K, Wirsing A, Lucas B, Klein-Hitpass L and Ryffel GU: HNF4α orchestrates a set of 14 genes to down-regulate cell proliferation in kidney cells. Biol Chem 389: 179-187, 2008. (Pubitemid 351170657)
20. Hnatyszyn HJ, Liu M, Hilger A, et al: Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody. Breast Cancer Res Treat 122: 371-380, 2010.
21. Sahab ZJ, Man YG, Byers SW and Sang QX: Putative biomarkers and targets of estrogen receptor negative human breast cancer. Int J Mol Sci 12: 4504-4521, 2011.
22. Ying M, Sang Y, Li Y, et al: Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells 29: 20-31, 2011.
23. Ding X, Zhang N, Cai Y, et al: Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma. Mol Oncol 6: 73-80, 2012.
24. Tan DS, Lambros MB, Rayter S, et al: PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 15: 2269-2280, 2009.
25. Ali AY, Abedini MR and Tsang BK: The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene 31: 2175-2186, 2012.
26. Paolella BR, Havrda MC, Mantani A, Wray CM, Zhang Z and Israel MA: p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. Stem Cells 29: 1090-1101, 2011.
27. Krupp M, Maass T, Marquardt JU, et al: The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. BMC Med Genomics 4: 53, 2011.
28. Lane D, Goncharenko-Khaider N, Rancourt C and Piche A: Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 29: 3519-3531, 2010.
29. Nakanishi T, Chumsri S, Khakpour N, et al: Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 102: 815-826, 2010.
30. Hardy KM, Booth BW, Hendrix MJ, Salomon DS and Strizzi L: ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 15: 191-199, 2010.
31. - tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer 9: 288, 2010.
32. Katoh M and Katoh M: STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review). Int J Mol Med 19: 273-278, 2007.
33. Bronowski C, Smith SL, Yokota K, et al: A subset of mucosa-associated Escherichia coli isolates from patients with colon cancer, but not Crohn's disease, share pathogenicity islands with urinary pathogenic E. coli. Microbiology 154: 571-583, 2008. (Pubitemid 351292311)
34. Bourseau-Guilmain E, Griveau A, Benoit JP and Garcion E: The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PLoS One 6: e25515, 2011.
35. Wu WK, Sung JJ, Wu YC, et al: Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochem Biophys Res Commun 382: 79-84, 2009.
36. Li W, Wang J, Jiang HR, et al: Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo. Int J Mol Sci 12: 668-681, 2011.
37. Silva IA, Bai S, McLean K, et al: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71: 3991-4001, 2011.
38. Kast RE and Belda-Iniesta C: Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis. Curr Stem Cell Res Ther 4: 314-317, 2009.
39. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA and Darwiche N: What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 15: 668-678, 2010.
40. Park SS, Park SK, Lim JH, Choi YH, Kim WJ and Moon SK: Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells. Oncol Rep 25: 223-230, 2011.
41. Nakamura Y: Retracted: Modulation of p53/Akt/phosphatase and tensin homolog expression by esculetin potentiates the anticancer activity of cisplatin and prevents its nephrotoxicity. Cancer Sci 103: 154, 2012.
42. Furusawa S, Nakano S, Wu J, et al: Apoptosis induced by doxorubicin and cinchonine in P388 multidrug-resistant cells. J Pharm Pharmacol 53: 1029-1039, 2001. (Pubitemid 32640287)
43. Lee SY, Rhee YH, Jeong SJ, et al: Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol 26: 424-431, 2011.
44. Donahue RN, McLaughlin PJ and Zagon IS: Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) 236: 883-895, 2011.
45. + cells with cancer stem cell characteristics. Breast Cancer Res 10: R10, 2008.
46. Sauvageot CM, Weatherbee JL, Kesari S, et al: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 11: 109-121, 2009.
47. Tatokoro M, Koga F, Yoshida S, et al: Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer 131: 987-996, 2012.
48. Yip NC, Fombon IS, Liu P, et al: Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 104: 1564-1574, 2011.